^
Association details:
Biomarker:AR overexpression
Cancer:HER2 Positive Breast Cancer
Regimen:TCHP (carboplatin + docetaxel + Herceptin (trastuzumab) + Perjeta (pertuzumab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

Published date:
02/11/2022
Excerpt:
A total of 90.9% of patients received neoadjuvant therapy of taxanes, carboplatin, trastuzumab and pertuzumab (TCHP), and the total pCR rate was 50%. pCR was...positively related to high expression levels of AR (OR 33.145 [95% CI 2.803–391.900], p = 0.005)....AR is a potential marker for the prediction of pCR in HER2-positive breast cancer patients treated with HP neoadjuvant therapy.
DOI:
https://doi.org/10.3390/jpm12020261